Nitric oxide inhibits the release of acetylcholine in the isolated retina.

BACKGROUND: Recent studies have revealed that administration of nitric oxide (NO) donors increases the release of neurotransmitters in various brain regions. In the retina, NO synthetase (NOS) is found in retinal amacrine and ganglion cells, and it is evident that NO is involved in encoding visual information. In the present study, therefore, NO donors were used to study the effect of exogenous NO on the high K(+)-evoked release of endogenous acetylcholine (ACh) in the rat retina. METHODS: Isolated rat retinal preparations were superfused with modified Krebs-Ringer bicarbonate buffer solution. In each experiment, stimulation for 10 min with 30 mM KCl was done twice. The amounts of ACh released by the first or second KCl stimulation were termed S1 and S2 respectively. Test agents were applied just before the second KCl stimulation. The effects of test agents were evaluated as S2 divided by S1. ACh was converted to hydrogen peroxide and electrochemically assayed by high-performance liquid chromatography. RESULTS: S-Nitro-N-acetyl-DL-penicillamine (SNAP), an NO donor, dose-dependently inhibited the high K(+)-evoked release of endogenous ACh. Such inhibition by NO was confirmed also by another NO donor, (+/-)-(E)-4-ethyl-2-[(E)-hydroxy imino]-5-nitro-3-hexenamide (NOR3). The inhibitory effect of SNAP was abolished by both carboxy-PTIO, an NO scavenger, and bicuculline, an antagonist of GABAA receptors. CONCLUSIONS: The NO-induced decrease of ACh release is probably due to an NO-induced increase of GABAergic system inhibition.

U-46619, a selective thromboxane A2 mimetic, inhibits the release of endogenous noradrenaline from the rat hippocampus in vitro.

Possible roles of thromboxane A2 (TXA2) in the release mechanism of hippocampal noradrenaline (NA) were examined in vitro. Slices or crude synaptosomes prepared from the rat hippocampus were superfused with modified Krebs-Ringer solution. Application of 20 mM KCl for 5 min increased the release of NA from the slices, and this release was consistently reproduced. Application of U-46619 (9,11-dideoxy-9alpha,11alpha-methanoepoxy prostaglandin F2alpha), a specific TXA2 mimetic, just before the second KCl (20 mM) stimulation decreased the KCl-evoked NA release in a concentration-dependent manner (10-100 microM). This U-46619 (50 microM)-induced inhibition of NA release was abolished by 10 microM SQ29548, a specific TXA2 receptor antagonist. In experiments with hippocampal crude synaptosomes, however, KCl (20 and 40 mM)-evoked release of NA was not attenuated by U-46619 (100 microM). Furthermore, the inhibitory effect of U-46619 (50 microM) in the sliced preparations was not modified by 100 microM (-)-bicuculline, a GABA(A)-receptor antagonist. The present results indicate that U-46619 inhibits the release of NA from the rat hippocampus by activation of TXA2 receptors. Activation of TXA2 receptors probably excites an unidentified but not GABAergic neuron system, thereby inhibiting the NA release from the rat hippocampus.

Effects of L-carnitine supplementation on cardiac morbidity in hemodialyzed patients.

Cardiac diseases are well known among patients on maintenance hemodialysis (HD), and carnitine deficiency may be an important factor in cardiac morbidity. We studied the effects of low-dose L-carnitine treatment (500 mg/day) on chest symptoms (dyspnea on exertion, chest pain, palpitation), cardiac function, and left ventricular (LV) mass in 9 HD patients with reduced ejection fraction (EF). After 6 months of L-carnitine treatment, most patients had at least some improvement in chest symptoms, while LVEF was increased and LV mass was decreased. Carnitine fractions increased and reached plateaus at 2-3 times the baseline levels. These results suggest that prolonged low-dose L-carnitine treatment can improve the cardiac morbidity by restoring decreased carnitine tissue levels and impaired oxidation of FFA.

Perfusion of the hypothalamic paraventricular nucleus with N-methyl-D-aspartate produces thromboxane A2 and centrally activates adrenomedullary outflow in rats.

We applied a microdialysis technique for the measurement of hypothalamic thromboxane B2, a stable metabolite of thromboxane A2, in urethane-anesthetized rats. Perfusion with N-methyl-D-aspartate (1.5 and 2.5mM) of the paraventricular nucleus by microdialysis probe concentration-dependently elevated the levels of thromboxane B2 in this region and plasma levels of catecholamines. The elevation of adrenaline was much more marked than that of noradrenaline. Pretreatment with dizocilpine maleate (0.1 mM), a non-competitive antagonist of N-methyl-D-aspartate receptors, of the paraventricular nucleus by microdialysis probe attenuated the N-methyl-D-aspartate (1.5 mM)-induced elevations of both thromboxane B2 and plasma catecholamines. Intracerebroventricular administration of furegrelate (250 microg/animal), a thromboxane A2 synthase inhibitor, also abolished the responses evoked by N-methyl-D-aspartate. These results indicate that N-methyl-D-aspartate applied into the paraventricular nucleus produces thromboxane A2 in this region and elevates plasma levels of catecholamines, especially adrenaline. Thromboxane A2 produced in this hypothalamic nucleus is probably involved in the N-methyl-D-aspartate-induced central adrenomedullary outflow.

Neurotransmitter contents in the retina of RCS rat.

BACKGROUND: Retinitis pigmentosa is a hereditary disease characterized by gradually developing degeneration of photoreceptors. The Royal College of Surgeons (RCS) rat is an experimental model of retinitis pigmentosa. However, there is a paucity of information concerning neurotransmitter contents in the retina of RCS rats. Thus, we determined the retinal contents of neurotransmitters in RCS rats at 4 and 23 weeks postnatally and in age-matched congenic control rats. METHODS: Dopamine (DA) and acetylcholine (ACh) were electrochemically measured by high-performance liquid chromatography (HPLC). Neuroactive amino acids, including gamma-aminobutyric acid (GABA) and taurine, were determined by means of an HPLC-precolumn derivatization method. RESULTS: Contents of DA, ACh, glutamate, aspartate and GABA in the retina of RCS rats 4 weeks postnatally were within normal ranges. At 23 weeks, the retinal contents of DA, glutamate and aspartate in the RCS rats were significantly lower than in the age-matched control rats, while the contents of ACh and GABA were unaffected even at this later stage. On the other hand, the retinal content of glycine in the RCS rats at 23 weeks was significantly higher than that in the age-matched control rats. It is interesting to note that the content of taurine in the RCS rats had already decreased at 4 weeks postnatally and the decrease was more marked at 23 weeks. CONCLUSION: The decrease in taurine content is probably the first sign of degeneration revealed by the retinal neurotransmitters of RCS rats.

Melatonin inhibits the central sympatho-adrenomedullary outflow in rats.

Central effects of melatonin on the sympatho-adrenomedullary outflow were investigated in urethane-anesthetized rats. In the intact animals, intracerebroventricularly (i.c.v.) administered interleukin-1beta (IL-1beta) (100 ng/animal) slightly, but significantly, elevated the plasma level of noradrenaline (NA), but not the level of adrenaline (Ad). Melatonin (100 microg/animal, i.c.v.) did not modulate the effects of IL-1beta on plasma levels of catecholamines. In the pinealectomized animals, however, the same dose of IL-1beta markedly elevated plasma levels of both Ad and NA, and the elevation of Ad was more potent than that of NA. In these pinealectomized animals, the serum level of melatonin was significantly lower than that in the sham-operated control animals. Furthermore, the IL-1beta-induced elevations of plasma catecholamines in these pinealectomized animals were attenuated by i.c.v. administered melatonin. These results suggest that melatonin plays an inhibitory role in the central regulation of sympatho-adrenomedullary outflow in rats.

Involvement of N-type voltage-activated Ca2+ channels in the release of endogenous noradrenaline from the isolated vascularly perfused rat stomach.

We characterized the voltage-activated Ca2+ channels involved in noradrenaline (NA) release from gastric sympathetic neurons using isolated, vascularly perfused rat stomach. The evoked NA release by electrical stimulation of periarterial nerves was abolished by calcium removal from the perfusion medium and by cadmium. Omega-conotoxin GVIA (N-type Ca2+-channel blocker) effectively and omega-conotoxin MVIIC (N/P/Q-type blocker) slightly inhibited the evoked NA, while omega-agatoxin IVA (P-type blocker) had no effect. These results suggest that omega-conotoxin GVIA and omega-conotoxin MVIIC-sensitive N-type Ca2+ channels are involved in NA release from the rat gastric sympathetic nerve terminals.

Involvement of mu-receptor in endogenous opioid peptide-mediated inhibition of acetylcholine release from the rat stomach.

We examined the effect of endogenous opioid peptides on vagally evoked release of acetylcholine (ACh) from the isolated, vascularly perfused rat stomach. The vagus nerves were electrically stimulated twice at 2.5 Hz for 2 min, and test substances were administered during the second stimulation. beta-Endorphin (10(-7) and 3 x 10(-7) M), an endogenous nonselective agonist of mu-receptors, inhibited the release of ACh. However, [Leu5]-enkephalin, an endogenous nonselective agonist of delta-receptors, and U-50488, a kappa-receptor agonist, had no effect at a higher dose of 10(-6) M. Beta-endorphin-induced inhibition was abolished by naloxone. Endomorphins 1 and 2 (3 x 10(-7) and 10(-6) M), endogenous selective agonists of mu-receptors, also inhibited the release of ACh. These results suggest that the mu-receptor is involved in the endogenous opioid peptide-induced inhibition of the release of ACh from the rat stomach.

Thromboxane A2 is involved in the nitric oxide-induced central activation of adrenomedullary outflow in rats.

The central effect of 3-morpholinosydnonimine, a nitric oxide donor, on the sympatho-adrenomedullary system was investigated in urethane-anesthetized rats. Intracerebroventricular administration of 3-morpholinosydnonimine (100, 250 and 500 microg/animal) induced a marked elevation of adrenaline levels and a slight elevation of noradrenaline levels in the plasma. These 3-morpholinosydnonimine (250 microg/animal)-induced elevations of catecholamines were abolished by intracerebroventricular treatments with 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-l-oxyl 3-oxide (750 microg/animal), a nitric oxide scavenger, and indomethacin (500 microg/animal), a cyclo-oxygenase inhibitor, but not with superoxide dismutase (250 units/animal), a superoxide anion scavenger. Furthermore, the 3-morpholinosydnonimine (250 microg/animal)-induced elevation of plasma adrenaline levels was abolished by intracerebroventricular treatments with thromboxane A2 synthase inhibitors [furegrelate (100, 250 and 1000 microg/animal) and carboxyheptyl imidazole (500 microg/animal)], and also with thromboxane A2 receptor blockers [(+)-S-145 (100, 250 and 1000microg/animal) and SQ29548 (8microg/animal)]. The elevation of noradrenaline levels was, however, not attenuated by these thromboxane A2-related test agents. The present results indicate that nitric oxide but not peroxynitrite markedly activates central adrenomedullary outflow. Thromboxane A2 in the brain is probably involved in this central activation of adrenomedullary outflow.

Properties of calcium channels coupled to endogenous glutamate release from the vascularly perfused rat stomach in vitro.

We have demonstrated that both high-K+ and electrical stimulation of the vagus nerves release endogenous glutamate from the vascularly-perfused rat stomach in a calcium-dependent manner. In the present study, we examined properties of calcium channel subtypes mediating endogenous glutamate release from the stomach. Application of 50 mM KCl elicited a release of glutamate, and this release was abolished in calcium-free medium. The release of glutamate was significantly inhibited by both omega-agatoxin IVA, a P/Q-type calcium channel antagonist, and isradipine, an L type calcium channel antagonist. Omega-conotoxin GVIA, an N type calcium channel antagonist and flunarizine, a nonselective T-type calcium channel antagonist were without effect. In contrast to this case of glutamate, omega-conotoxin GVIA induced a marked inhibition in the release of gastric noradrenaline. The combined treatment with omega-agatoxin IVA plus isradipine produced a marked synergistic inhibition of the glutamate release. This inhibition was, however, much less than that by cadmium. The present results suggest that P/Q and L type calcium channels coexist to regulate the release of gastric glutamate. Furthermore, it is possible that unidentified calcium channels other than P/Q and L type channels are also involved in the release of glutamate in the stomach.

Centrally applied nitric oxide donors inhibit vagally evoked rat gastric acid secretion: involvement of sympathetic outflow.

ntracerebroventricularly (i.c.v.) administered nitric oxide (NO) donors, 3-morpholinosydnonimine (SIN-1) (100-500 microg/animal) and sodium nitroprusside (SNP) (100-250 microg/animal) dose-dependently inhibited the rat gastric acid secretion evoked by vagal stimulation at 3 Hz. Furthermore, the inhibitory effect of SIN-1 (250 microg/animal) was more marked and its onset was more rapid than that of SNP (250 microg/animal). The SIN-1 (250 microg/animal)-induced antisecretory effect was abolished by both splanchnicotomy and phentolamine (5 mg/kg, i.m.), and also by indomethacin (500 microg/animal, i.c.v.). These results suggest that i.c.v. administered NO donors inhibit vagally evoked gastric acid secretion by activation of central sympathetic outflow. Central prostaglandin is probably implicated in this NO-mediated antisecretory effect.

Brain histamine mediates the bombesin-induced central activation of sympatho-adrenomedullary outflow.

Intracerebroventricular (i.c.v.) administration of bombesin (0.3 nmol) increased plasma levels of both adrenaline and noradrenaline in urethane anesthetized rats. These bombesin-induced increases were inhibited by i.c.v. pretreatment with pyrilamine, an H1-receptor antagonist. Ranitidine, an H2-receptor antagonist also inhibited the increase of adrenaline, however, its effective dose was much larger than that of pyrilamine. Furthermore, the bombesin-induced increase of noradrenaline was not effectively inhibited by ranitidine. In the next series, turnover of histamine was assessed by measuring accumulation of tele-methylhistamine (t-MH), a major metabolite of brain histamine. I.c.v. administration of bombesin (0.3-3 nmol) increased turnover of hypothalamic histamine, while its intravenous administration was without effect. The present results suggest that the bombesin-induced central activation of sympatho-adrenomedullary outflow is probably, at least in part, mediated through brain histaminergic neurons.

Nitric oxide mediates central activation of sympathetic outflow induced by interleukin-1 beta in rats.

The excitatory mechanism of central sympathetic outflow induced by interleukin-1 beta was investigated in urethane-anesthetized rats. Intracerebroventricular administration of interleukin-1 beta induced a gradually developing elevation of plasma noradrenaline levels in a dose-dependent manner (50, 100 and 200 ng/animal), while the levels of adrenaline were not affected. The elevation of noradrenaline levels induced by interleukin-1 beta (100 ng/animal i.c.v.) was abolished by the following treatments with: (1) a chemical sympathectomizer, 6-hydroxydopamine (15 mg/kg i.v., 3 days before); (2) a prostaglandin synthesis inhibitor, indomethacin (500 micrograms/animal i.c.v.); (3) a nitric oxide synthase inhibitor, L-NG-nitroarginine methyl ester (100 micrograms plus 10 micrograms/min i.c.v.); and (4) a nitric oxide scavenger, oxyhemoglobin (32.3 micrograms plus 3.23 micrograms/min i.c.v.). In contrast to these results, D-NG-nitroarginine methyl ester, an inactive isomer of L-NG-nitroarginine methyl ester, and methemoglobin, a metabolite of oxyhemoglobin, were without effect. Furthermore, prostaglandin E2 (100 ng/animal i.c.v.) rapidly and markedly elevated the plasma level of noradrenaline but not adrenaline. This prostaglandin E2-induced elevation of plasma noradrenaline levels was not attenuated by L-NG-nitroarginine methyl ester (100 micrograms plus 10 micrograms/min i.c.v.). The present results suggest that nitric oxide is involved in the interleukin-1 beta-induced central activation of sympathetic outflow. Furthermore, there probably exists nitric oxide-linked prostaglandin-generating system in the brain.

Calcium-dependent release of endogenous glutamate from vascularly perfused rat stomach in vitro.

To investigate a possible physiological role for glutamate in the stomach, release of endogenous glutamate from an isolated vascularly-perfused rat stomach preparation was studied. Glutamate was measured by the bioluminescence assay method. High concentrations of KCI (30-75 mM) induced a dose-dependent release of glutamate. This KCI-induced release of glutamate was abolished in calcium-free medium containing ethylene glycol bis (beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA). Electrical stimulation of the vagus nerves also induced a release of glutamate. This vagal stimulation-induced release of glutamate was abolished by both calcium removal and tetrodotoxin (TTX). Amounts of 13 other amino acids in the medium, detectable by the automatic amino-acid analyzer, were not significantly affected by both high-K+ and the vagal stimulation. These results provide additional evidence that glutamate probably serves as a neurotransmitter in the stomach.

Inhibition of vagally mediated gastric acid secretion by activation of central prostanoid EP3 receptors in urethane-anaesthetized rats.

1. We studied the effects of intracerebroventricular (i.c.v.) administration of prostanoid EP receptor ligands on vagally stimulated gastric acid secretion in rats anaesthetized with urethane. 2. Administration of misoprostol (EP3/EP2 receptor agonist) and sulprostone (EP3/EP1 receptor agonist) reduced vagally mediated gastric acid secretion in a dose-dependent manner (0.1, 0.3 and 1.0 nmol per animal). Butaprost (EP2 receptor agonist) (0.3 and 3.0 nmol per animal) was without effect. 17-Phenyl-omega- trinor PGE2 (EP1/EP3 receptor agonist) attenuated vagally mediated gastric acid secretion only at its highest dose (1.0 nmol per animal); this antisecretory effect was not prevented by pretreatment with SC-19220 (selective EP1 receptor antagonist) (20 nmol per animal, i.c.v.). 3. The potency of these test agents in attenuation of vagally mediated gastric acid secretion was as follows: misoprostol > or = sulprostone > > 17-phenyl-omega-trinor PGE2 > > > butaprost. These results suggest that activation of central prostanoid EP3 receptors induces inhibition of vagally mediated gastric acid secretion in rats.

Brain prostaglandins mediate the bombesin-induced increase in plasma levels of catecholamines.

Intracerebroventricular (i.c.v.) administration of bombesin (0.1, 1.0, 10.0 nmol/animal) in urethane-anesthetized rats induced long-lasting and dose dependent increases in plasma levels of adrenaline and noradrenaline. These effects of bombesin were inhibited by i.c.v. pretreatment with indomethacin (50-500 micrograms/animal), while the same dose of indomethacin by the intravenous route was without effect. The bombesin-induced increases in plasma levels of catecholamines were also inhibited by i.c.v. pretreatment with diclofenac (100-500 micrograms/animal), a cyclooxygenase inhibitor other than indomethacin. I.c.v. administration of thyrotropin releasing hormone (TRH) (10 nmol/animal) also induced increases in plasma levels of adrenaline and noradrenaline, however, these increases were not modified by i.c.v. pretreatment with indomethacin. The present results suggest that the bombesin-induced increases in plasma levels of catecholamines are probably due to prostaglandins synthetized in the brain with this neuropeptide. Furthermore, it is likely that prostaglandins are not always involved in central activation of sympatho-adrenomedullary system by other brain neuropeptides.

Recombinant interleukin-1 beta inhibits gastric acid secretion by activation of central sympatho-adrenomedullary outflow in rats.

The inhibitory mechanism of gastric acid secretion induced by human recombinant interleukin-1 beta was investigated in bilaterally vagotomized, urethane-anesthetized rats. Intracerebroventricular administration of interleukin-1 beta (10, 50 and 100 ng/animal) dose dependently inhibited the gastric acid secretion induced by electrical stimulation of the vagus nerve at 3 Hz. Inhibition of gastric acid secretion induced by interleukin-1 beta (50 ng/animal) was abolished both by splanchnectomy and by phentolamine (5 mg/kg i.m.). Greater splanchnic nerves ramify into the adrenal branch and gastric sympathetic preganglionic branch. The interleukin-1 beta (50 ng/animal)-induced inhibition was also abolished by intracerebroventricular pretreatment with indomethacin (500 micrograms/animal), while pretreatment with the same dose of this reagent by the intraperitoneal route was without effect. These results suggest that centrally administered interleukin-1 beta induces a prostaglandin-mediated central excitation of the sympatho-adrenomedullary system, and the resultant activation of gastric alpha-adrenoceptors inhibits the vagally stimulated gastric acid secretion in rats.

Centrally applied bombesin increases nerve activity of both sympathetic and adrenal branch of the splanchnic nerves.

We reported that centrally applied bombesin probably excites both the gastric sympathetic and adrenomedullary systems and thus induces inhibition of gastric acid secretion. In the present study, therefore, we examined whether or not centrally applied bombesin directly affects sympathetic nerve activities in rats anesthetized with urethane. Intracerebroventricular administration of bombesin (0.3 and 3.0 nmol) increased discharge rates of the sympathetic branch as well as those of the adrenal branch of preganglionic greater splanchnic nerves. These effects were not secondary to changes in arterial blood pressure by bombesin. In conclusion, centrally applied bombesin directly activates both the sympathetic and adrenomedullary systems.

Elevation of plasma noradrenaline levels in urethane-anaesthetized rats by activation of central prostanoid EP3 receptors.

1. We studied the effects of intracerebroventricular (i.c.v.) administration of prostaglandin E2 (PGE2) and its receptor subtype ligands on plasma levels of catecholamines in urethane-anaesthetized rats. 2. Administration of PGE2 (0.15, 0.3 and 1.5 nmol per animal, i.c.v.) dose-dependently elevated plasma levels of noradrenaline (NA), while the levels of adrenaline were not affected. 3. Administration of sulprostone (EP3/EP1 agonist) and misoprostol (EP3/EP2 agonist) effectively elevated plasma NA levels in a dose-dependent manner (0.1, 0.3, and 1.0 nmol per animal). Butaprost (EP2 agonist) (0.3, 1.0 and 3.0 nmol per animal) was without effect. 17-Phenyl-omega-trinor PGE2 (EP1/EP3 agonist) effectively elevated plasma NA levels only at its highest dose (1.0 nmol per animal), but this elevation was not attenuated by pretreatment with SC-19220 (selective EP1 antagonist) (20 nmol per animal, i.c.v.). 4. The potency of these test agents in elevating plasma levels of NA was as follows; misoprostol > sulprostone > PGE2 > > 17-phenyl-omega-trinor PGE2 > > > butaprost. These results suggest that activation of central prostanoid EP3-receptors induces central sympathetic outflow in rats.

Properties of the voltage-gated calcium channels mediating dopamine and acetylcholine release from the isolated rat retina.

We examined the properties of voltage-gated calcium channels mediating endogenous dopamine (DA) and acetylcholine (ACh) release in the isolated rat retina. Application of 30 mM KCl elicited the release of DA and ACh, and these releases were abolished in Ca(2+)-free medium. The high K(+)-evoked DA release was largely blocked by both of omega-agatoxin IVA and omega-conotoxin MVIIC, P- and Q-type calcium channel antagonists, and partly blocked by isradipine, and L-type calcium channel antagonist, and omega-conotoxin GVIA, an N-type calcium channel antagonist. omega-Agatoxin IVA at a small dose, sufficient to block P-type channels alone, was however without effect. On the other hand, the high K(+)-evoked ACh release was partly blocked by omega-agatoxin IVA and omega-conotoxin MVIIC, but was resistant to isradipine and omega-conotoxin GVIA. Flunarizine, a non-selective T-type calcium channel antagonist, did not inhibit the release of DA and ACh. Cd2+ markedly blocked the release of both DA and ACh, Co2+ and Ni2+ slightly blocked the release of DA, and the release of ACh was not blocked by these two divalent cations. These results suggest that the high K(+)-evoked release of retinal DA is largely mediated by omega-agatoxin IVA and omega-conotoxin MVIIC sensitive calcium channels (probably Q-type channels), while the release of retinal ACh is largely mediated by as yet uncharacterized Cd2+ sensitive calcium channels. The properties of voltage-gated calcium channels involved in the release of ACh in the rat retina differ from those of DA.